Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UP360 is a proprietary botanical blend developed by Unigen Inc., composed of standardized polysaccharide and polyphenol extracts from *Aloe vera* gel, *Poria cocos* mushroom, and rosemary. Positioned as a nutraceutical ingredient for immune homeostasis, it exerts antioxidant, anti-inflammatory, and immunomodulatory effects. In a randomized, triple-blind, placebo-controlled clinical trial involving healthy adults receiving seasonal influenza vaccination, UP360 was shown to significantly increase influenza B-specific IgG antibodies and glutathione peroxidase levels, suggesting it supports a robust immune response and may help prevent flu and flu-like symptoms. The formulation specifically targets immune cell populations such as gamma delta T-cells and various lymphocyte subsets to maintain immune balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UP360.